Nelson Joel, Saggau David D, Nielsen Jared S
*Des Moines University, Des Moines, Iowa; and †Wolfe Eye Clinic, West Des Moines, Iowa.
Retin Cases Brief Rep. 2014 Winter;8(1):70-2. doi: 10.1097/ICB.0000000000000007.
The purpose of this report is to present a case of hepatotoxicity secondary to off-label rifampin therapy for the treatment of chronic central serous choroidopathy.
Case report.
A patient with chronic central serous chorioretinopathy was treated with oral rifampin. Three weeks after the initiation of therapy, fatigue, nausea, and malaise associated with elevated liver enzyme elevations were noted. Symptoms resolved and liver enzymes normalized after discontinuing rifampin.
Rifampin-induced hepatic injury can occur during therapy for chronic central serous chorioretinopathy. Potential hepatotoxicity must be considered and followed closely during off-label rifampin treatment.
本报告旨在呈现一例因使用利福平进行标签外治疗慢性中心性浆液性脉络膜病变而继发肝毒性的病例。
病例报告。
一名慢性中心性浆液性脉络膜视网膜病变患者接受了口服利福平治疗。治疗开始三周后，出现了与肝酶升高相关的疲劳、恶心和不适。停用利福平后症状缓解，肝酶恢复正常。
在慢性中心性浆液性脉络膜视网膜病变的治疗过程中，可能会发生利福平诱导的肝损伤。在利福平标签外治疗期间，必须考虑潜在的肝毒性并密切随访。
Zotero 插件